DNA Repair Gene Polymorphisms Predict Favorable Clinical Outcome in Advanced Non–Small-Cell Lung Cancer

Spiro, 2005, The treatment of advanced non-small cell lung cancer, Curr Opin Pulm Med, 11, 287, 10.1097/01.mcp.0000166590.03042.56

Kelly, 2001, Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial, J Clin Oncol, 19, 3210, 10.1200/JCO.2001.19.13.3210

Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N Engl J Med, 346, 92, 10.1056/NEJMoa011954

Ikeda, 2001, Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum, Mol Cell Biochem, 219, 51, 10.1023/A:1011083429704

Nagata, 2001, Reversal of cisplatin and multidrug resistance by ribozyme-mediated glutathione suppression, Biochem Biophys Res Commun, 286, 406, 10.1006/bbrc.2001.5399

Goto, 2002, Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs, Jpn J Cancer Res, 93, 1047, 10.1111/j.1349-7006.2002.tb02482.x

Watson, 1998, Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution, Carcinogenesis, 19, 275, 10.1093/carcin/19.2.275

Zimniak, 1994, Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties, Eur J Biochem, 224, 893, 10.1111/j.1432-1033.1994.00893.x

Hayes, 1995, The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance, Crit Rev Biochem Mol Biol, 30, 445, 10.3109/10409239509083491

de las Penas, 2006, Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients, Ann Oncol, 17, 668, 10.1093/annonc/mdj135

Shen, 1998, Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans, Cancer Res, 58, 604

Yu, 2000, Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene, Int J Oncol, 16, 555

Yu, 1997, A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues, Mutat Res, 382, 13, 10.1016/S1383-5726(97)00004-6

Rosell, 2004, Molecular predictors of response to chemotherapy in lung cancer, Semin Oncol, 31, 20, 10.1053/j.seminoncol.2003.12.011

Duell, 2000, Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells, Carcinogenesis, 21, 965, 10.1093/carcin/21.5.965

Quintela-Fandino, 2006, DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy, J Clin Oncol, 24, 4333, 10.1200/JCO.2006.05.8768

Ding, 2003, LDA–a java-based linkage disequilibrium analyzer, Bioinformatics, 19, 2147, 10.1093/bioinformatics/btg276

Benhamou, 2005, ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review, Am J Epidemiol, 161, 1, 10.1093/aje/kwi018

Booton, 2006, Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer, J Thorac Oncol, 1, 679, 10.1097/01243894-200609000-00013

Booton, 2006, Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer, Cancer, 106, 2421, 10.1002/cncr.21885

Gurubhagavatula, 2004, XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy, J Clin Oncol, 22, 2594, 10.1200/JCO.2004.08.067

Ryu, 2004, Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy, Lung Cancer, 44, 311, 10.1016/j.lungcan.2003.11.019

Zhou, 2004, Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy, Clin Cancer Res, 10, 4939, 10.1158/1078-0432.CCR-04-0247

Su, 2007, Genetic polymorphisms and treatment response in advanced non-small cell lung cancer, Lung Cancer, 56, 281, 10.1016/j.lungcan.2006.12.002

Smith, 2007, ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy, J Clin Oncol, 25, 5172, 10.1200/JCO.2007.11.8547

Robinson, 1984, Codon usage can affect efficiency of translation of genes in Escherichia coli, Nucleic Acids Res, 12, 6663, 10.1093/nar/12.17.6663

Suk, 2005, Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients, Clin Cancer Res, 11, 1534, 10.1158/1078-0432.CCR-04-1953

McGurk, 2006, Regulation of DNA repair gene expression in human cancer cell lines, J Cell Biochem, 97, 1121, 10.1002/jcb.20711

Olaussen, 2006, DNA repair by ERCC1 in non-smallcell lung cancer and cisplatin-based adjuvant chemotherapy, N Engl J Med, 355, 983, 10.1056/NEJMoa060570

Ceppi, 2006, ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine, Ann Oncol, 17, 1818, 10.1093/annonc/mdl300

Britten, 2000, ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells, Int J Cancer, 89, 453, 10.1002/1097-0215(20000920)89:5<453::AID-IJC9>3.0.CO;2-E

Lunn, 1999, XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency, Cancer Res, 59, 2557

Monaco, 2007, Conformational effects of a common codon 399 polymorphism on the BRCT1 domain of the XRCC1 protein, Protein J, 26, 541, 10.1007/s10930-007-9095-y

Giachino, 2007, Prospective assessment of XPD Lys-751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer, Clin Cancer Res, 13, 2876, 10.1158/1078-0432.CCR-06-2543

Stoehlmacher, 2001, A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer, Anticancer Res, 21, 3075

Zhou, 2005, Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer, Cancer Epidemiol Biomarkers Prev, 14, 491, 10.1158/1055-9965.EPI-04-0612